{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:04:57Z","timestamp":1791227097317,"version":"4.1.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Receptor-interacting serine\/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor kappa B (NF-\u03baB) and mitogen-activated protein kinases (MAPK), followed by the production of pro-inflammatory cytokines such as TNF-\u03b1, IL-6, and IL-12\/23. Defects in NOD\/RIPK2 signaling are associated with numerous inflammatory diseases, including asthma, sarcoidosis, inflammatory bowel disease (Crohn\u2019s disease and ulcerative colitis), multiple sclerosis, and Blau syndrome. As RIPK2 is a crucial element of innate immunity, small molecules regulating RIPK2 functions are attractive to establish novel immunotherapies. The increased interest in developing RIPK2 inhibitors has led to the clinical investigations of novel drug candidates. In this review, we attempt to summarize recent advances in the development of RIPK2 inhibitors and degraders.<\/jats:p>","DOI":"10.3389\/fphar.2023.1127722","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:05:41Z","timestamp":1678169141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases"],"prefix":"10.3389","volume":"14","author":[{"given":"Anh-Tuan","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Franceschini","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.cub.2004.12.032","article-title":"The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO","volume":"14","author":"Abbott","year":"2004","journal-title":"Curr. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1128\/MCB.00270-07","article-title":"Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains","volume":"27","author":"Abbott","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11010-005-3701-0","article-title":"Inhibition of RIP2\/RIck\/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK","volume":"268","author":"Argast","year":"2005","journal-title":"Mol. Cell Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u20132021): Medical indication, Pharmacology, and synthesis (1995-2021): Medical indication, Pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.immuni.2009.04.011","article-title":"Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2","volume":"30","author":"Bertrand","year":"2009","journal-title":"Immunity."},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: Progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1158\/0008-5472.379.65.2","article-title":"Cellular targets of gefitinib","volume":"65","author":"Brehmer","year":"2005","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.chembiol.2015.07.017","article-title":"Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors","volume":"22","author":"Canning","year":"2015","journal-title":"Chem. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.immuni.2014.12.010","article-title":"NOD1 and NOD2: Signaling, host defense, and inflammatory disease","volume":"41","author":"Caruso","year":"2014","journal-title":"Immunity."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1172\/JCI124617","article-title":"The balance of power: Innate lymphoid cells in tissue inflammation and repair","volume":"129","author":"Castellanos","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/ni945","article-title":"An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid","volume":"4","author":"Chamaillard","year":"2003","journal-title":"Nat. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1016\/j.bmc.2015.09.038","article-title":"Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity","volume":"23","author":"Charnley","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","article-title":"NOD-like receptors: Role in innate immunity and inflammatory disease","volume":"4","author":"Chen","year":"2009","journal-title":"Annu. Rev. Pathology Mech. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"eaay8230","DOI":"10.1126\/sciadv.aay8230","article-title":"Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists","volume":"6","author":"Chen","year":"2020","journal-title":"Sci. Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/416190a","article-title":"Involvement of receptor-interacting protein 2 in innate and adaptive immune responses","volume":"416","author":"Chin","year":"2002","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: Progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B19","unstructured":"Iclusig"},{"key":"B20","unstructured":"Iressa"},{"key":"B21","unstructured":"Nexavar2007"},{"key":"B22","unstructured":"Stivarga"},{"key":"B23","unstructured":"Tarceva"},{"key":"B24","doi-asserted-by":"publisher","first-page":"G500","DOI":"10.1152\/ajpgi.00163.2021","article-title":"The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease","volume":"321","author":"Ermann","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.gendis.2021.10.007","article-title":"Role of receptor interacting protein (RIP) kinases in cancer","volume":"9","author":"Ermine","year":"2022","journal-title":"Genes Dis."},{"key":"B26","unstructured":"Erlotinib (tarceva)2016"},{"key":"B27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: The road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e34375","DOI":"10.1371\/journal.pone.0034375","article-title":"The tandem CARDs of NOD2: Intramolecular interactions and recognition of RIP2","volume":"7","author":"Fridh","year":"2012","journal-title":"PLoS One."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1126\/science.1084677","article-title":"Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan","volume":"300","author":"Girardin","year":"2003","journal-title":"Science."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1074\/jbc.C200651200","article-title":"Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection","volume":"278","author":"Girardin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0206244","DOI":"10.1371\/journal.pone.0206244","article-title":"CARD domain of rat RIP2 kinase: Refolding, solution structure, pH-dependent behavior and protein-protein interactions","volume":"13","author":"Goncharuk","year":"2018","journal-title":"PLoS One."},{"key":"B32","doi-asserted-by":"publisher","first-page":"13535","DOI":"10.1021\/ja303883c","article-title":"The innate immune protein Nod2 binds directly to MDP, a bacterial cell wall fragment","volume":"134","author":"Grimes","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1021\/acsmedchemlett.9b00141","article-title":"Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors","volume":"10","author":"Haffner","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1021\/acsmedchemlett.8b00344","article-title":"Identification of quinoline-based RIP2 kinase inhibitors with an improved therapeutic index to the hERG ion channel","volume":"9","author":"Haile","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1021\/acs.jmedchem.9b00575","article-title":"Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases","volume":"62","author":"Haile","year":"2019","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1021\/acs.jmedchem.6b00211","article-title":"The identification and pharmacological characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase","volume":"59","author":"Haile","year":"2016","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/eji.200737393","article-title":"RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses","volume":"38","author":"Hall","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.emboj.7601962","article-title":"A critical role of RICK\/RIP2 polyubiquitination in Nod-induced NF-kappaB activation","volume":"27","author":"Hasegawa","year":"2008","journal-title":"Embo J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"29054","DOI":"10.1074\/jbc.M602638200","article-title":"Differential release and distribution of Nod1 and Nod2 immunostimulatory molecules among bacterial species and environments","volume":"281","author":"Hasegawa","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1021\/acsmedchemlett.7b00258","article-title":"Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases","volume":"8","author":"He","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ibd\/izaa045","article-title":"Resolution of inflammation and gut repair in IBD: Translational steps towards complete mucosal healing","volume":"26","author":"Ho","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"14981","DOI":"10.1074\/jbc.M500966200","article-title":"Inhibition of RICK\/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease","volume":"280","author":"Hollenbach","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ab.2009.04.033","article-title":"Evaluating the utility of the HTRF transcreener ADP assay technology: A comparison with the standard HTRF assay technology","volume":"391","author":"Hong","year":"2009","journal-title":"Anal. Biochem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"650403","DOI":"10.3389\/fphar.2021.650403","article-title":"RIPK2 as a new therapeutic target in inflammatory bowel diseases","volume":"12","author":"Honjo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: From bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.1236381","article-title":"Crystal structure of NLRC4 reveals its autoinhibition mechanism","volume":"341","author":"Hu","year":"2013","journal-title":"Science."},{"key":"B48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/cdd.2014.126","article-title":"RIP kinases: Key decision makers in cell death and innate immunity","volume":"22","author":"Humphries","year":"2015","journal-title":"Cell Death Differ."},{"key":"B50","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/hmg\/ddi087","article-title":"NOD1 variation, immunoglobulin E and asthma","volume":"14","author":"Hysi","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"12296","DOI":"10.1074\/jbc.273.20.12296","article-title":"RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis","volume":"273","author":"Inohara","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"27823","DOI":"10.1074\/jbc.M003415200","article-title":"An induced proximity model for NF-kappa B activation in the Nod1\/RICK and RIP signaling pathways","volume":"275","author":"Inohara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1074\/jbc.C200673200","article-title":"Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease","volume":"278","author":"Inohara","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chom.2014.04.001","article-title":"The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling","volume":"15","author":"Irving","year":"2014","journal-title":"Cell Host Microbe."},{"key":"B55","doi-asserted-by":"publisher","first-page":"11964","DOI":"10.1074\/jbc.M707750200","article-title":"The role of RIP2 in p38 MAPK activation in the stressed heart","volume":"283","author":"Jacquet","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1189\/jlb.0213109","article-title":"RIP2 activity in inflammatory disease and implications for novel therapeutics","volume":"94","author":"Jun","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/hmg\/ddy132","article-title":"A hyperactivating proinflammatory RIPK2 allele associated with early-onset osteoarthritis","volume":"27","author":"Jurynec","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/416194a","article-title":"RICK\/Rip2\/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems","volume":"416","author":"Kobayashi","year":"2002","journal-title":"Nature."},{"key":"B60","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"23818","DOI":"10.1074\/jbc.M109.033670","article-title":"pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16442","article-title":"A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis","author":"Lee","year":"2022","journal-title":"Febs J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1086\/339432","article-title":"CARD15\/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease","volume":"70","author":"Lesage","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e11692","DOI":"10.7554\/eLife.11692","article-title":"Structural basis of death domain signaling in the p75 neurotrophin receptor","volume":"4","author":"Lin","year":"2015","journal-title":"Elife."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1039\/c5mb00212e","article-title":"Structural and functional insights into CARDs of zebrafish (Danio rerio) NOD1 and NOD2, and their interaction with adaptor protein RIP2","volume":"11","author":"Maharana","year":"2015","journal-title":"Mol. Biosyst."},{"key":"B66","doi-asserted-by":"publisher","first-page":"13349","DOI":"10.1021\/acs.jpcb.1c06176","article-title":"Structural elucidation of inter-CARD interfaces involved in NOD2 tandem CARD association and RIP2 recognition","volume":"125","author":"Maharana","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"B67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1074\/jbc.M110.189308","article-title":"A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses","volume":"286","author":"Marinis","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"16968","DOI":"10.1074\/jbc.273.27.16968","article-title":"RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase","volume":"273","author":"McCarthy","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/hmg\/ddi135","article-title":"Association between a complex insertion\/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease","volume":"14","author":"McGovern","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: Past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a series of RIPK2 PROTACs","volume":"64","author":"Miah","year":"2021","journal-title":"J. Med. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"23057","DOI":"10.1074\/jbc.M112.344283","article-title":"Pathogen sensing by nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP","volume":"287","author":"Mo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1038\/ncomms7442","article-title":"A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production","volume":"6","author":"Nachbur","year":"2015","journal-title":"Nat. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13133","article-title":"Endosomes are specialized platforms for bacterial sensing and NOD2 signalling","volume":"509","author":"Nakamura","year":"2014","journal-title":"Nature."},{"key":"B76","doi-asserted-by":"publisher","first-page":"33684","DOI":"10.1074\/jbc.274.47.33684","article-title":"RIP2 is a Raf1-activated mitogen-activated protein kinase kinase","volume":"274","author":"Navas","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ibd.20907","article-title":"Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease","volume":"15","author":"Negroni","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1074\/jbc.M008072200","article-title":"Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB","volume":"276","author":"Ogura","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"625710","DOI":"10.3389\/fmed.2021.625710","article-title":"Genetics of beh\u00e7et's disease: Functional genetic analysis and estimating disease heritability","volume":"8","author":"Ortiz-Fern\u00e1ndez","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.4049\/jimmunol.178.4.2380","article-title":"RICK\/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs","volume":"178","author":"Park","year":"2007","journal-title":"J. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"9594","DOI":"10.3390\/ijms15069594","article-title":"NOD-like receptors in intestinal homeostasis and epithelial tissue repair","volume":"15","author":"Parlato","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0177161","DOI":"10.1371\/journal.pone.0177161","article-title":"Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation","volume":"12","author":"Pellegrini","year":"2017","journal-title":"PLoS One."},{"key":"B83","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.molmed.2018.01.004","article-title":"Inflammasome, inflammation, and tissue homeostasis","volume":"24","author":"Rathinam","year":"2018","journal-title":"Trends Mol. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/BOR.0b013e328349c430","article-title":"Blau syndrome revisited","volume":"23","author":"Rose","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1021\/acsmedchemlett.0c00591","article-title":"Novel thienopyridines as RIPK2 inhibitors for treating inflammatory bowel disease","volume":"11","author":"Sabnis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"B86","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/prot.25756","article-title":"Modeling conformational flexibility of kinases in inactive states","volume":"87","author":"Schwarz","year":"2019","journal-title":"Proteins."},{"key":"B87","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.immuni.2010.12.015","article-title":"Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity","volume":"34","author":"Shaw","year":"2011","journal-title":"Immunity."},{"key":"B88","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12193","article-title":"Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease","volume":"260","author":"Strober","year":"2014","journal-title":"Immunol. Rev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ibd.20332","article-title":"Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease","volume":"14","author":"Stronati","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.dld.2010.04.003","article-title":"Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis","volume":"42","author":"Stronati","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ng.3786","article-title":"Dense genotyping of immune-related loci implicates host responses to microbial exposure in Beh\u00e7et's disease susceptibility","volume":"49","author":"Takeuchi","year":"2017","journal-title":"Nat. Genet."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.4049\/jimmunol.1600258","article-title":"Dual inhibition of Rip2 and IRAK1\/4 regulates IL-1\u03b2 and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells","volume":"197","author":"Talreja","year":"2016","journal-title":"J. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.emboj.7600175","article-title":"Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition","volume":"23","author":"Tanabe","year":"2004","journal-title":"Embo J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbadis.2006.07.006","article-title":"Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes","volume":"1762","author":"Tanabe","year":"2006","journal-title":"Biochim. Biophys. Acta."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cub.2009.06.038","article-title":"ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways","volume":"19","author":"Tao","year":"2009","journal-title":"Curr. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/s0960-9822(07)00352-1","article-title":"Identification of CARDIAK, a RIP-like kinase that associates with caspase-1","volume":"8","author":"Thome","year":"1998","journal-title":"Curr. Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1101\/gad.1964410","article-title":"Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses","volume":"24","author":"Tigno-Aranjuez","year":"2010","journal-title":"Genes Dev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"29651","DOI":"10.1074\/jbc.M114.591388","article-title":"In vivo inhibition of RIPK2 kinase alleviates inflammatory disease","volume":"289","author":"Tigno-Aranjuez","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.4049\/jimmunol.1004190","article-title":"Joint NOD2\/RIPK2 signaling regulates IL-17 axis and contributes to the development of experimental arthritis","volume":"188","author":"Vieira","year":"2012","journal-title":"J. Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/intimm\/dxz045","article-title":"RICK\/RIP2 is a NOD2-independent nodal point of gut inflammation","volume":"31","author":"Watanabe","year":"2019","journal-title":"Int. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nature02794","article-title":"De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling","volume":"430","author":"Wertz","year":"2004","journal-title":"Nature."},{"key":"B102","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20061704","article-title":"Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide","volume":"404","author":"Windheim","year":"2007","journal-title":"Biochem. J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/leu.2016.151","article-title":"Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML","volume":"30","author":"Wu","year":"2016","journal-title":"Leukemia."},{"key":"B104","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni.2669","article-title":"Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis","volume":"14","author":"Yang","year":"2013","journal-title":"Nat. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"36223","DOI":"10.1074\/jbc.M703079200","article-title":"NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B106","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1021\/acs.jmedchem.2c00604","article-title":"Discovery of potent and selective receptor-interacting serine\/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDs)","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1159\/000362972","article-title":"The E3 ligase RNF34 is a novel negative regulator of the NOD1 pathway","volume":"33","author":"Zhang","year":"2014","journal-title":"Cell Physiol. biochem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1127722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T06:05:47Z","timestamp":1678169147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1127722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":108,"alternative-id":["10.3389\/fphar.2023.1127722"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1127722","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"article-number":"1127722"}}